



Supplementary Fig. S21. Progression free survival in *POLE*-mutant EC [3,21]. *POLE*, DNA polymerase epsilon; EC, endometrial carcinoma.

References

1. Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. *Br J Cancer* 2015; 113: 299-310.
2. Eggink FA, Van Gool IC, Leary A, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies *POLE*-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. *Oncoimmunology* 2017; 6: e1264565.
3. Karnezis AN, Leung S, Magrill J, et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. *J Pathol Clin Res* 2017; 3: 279-93.
4. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. *Cancer* 2017; 123: 802-13.
5. Abdulfatah E, Wakeling E, Sakr S, et al. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: towards early personalized patient management. *Gynecol Oncol* 2019; 154: 467-74.
6. Wong A, Kuick CH, Wong WL, et al. Mutation spectrum of *POLE* and *POLD1* mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas. *Gynecol Oncol* 2016; 141: 113-20.

7. Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. *Clin Cancer Res* 2016; 22: 4215-24.
8. Imboden S, Nastic D, Ghaderi M, et al. Phenotype of *POLE*-mutated endometrial cancer. *PLoS One* 2019; 14: e0214318.
9. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of *POLE* proofreading mutations in endometrial cancer. *J Natl Cancer Inst* 2015; 107: 402.
10. Talhouk A, Hoang LN, McConechy MK, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment. *Gynecol Oncol* 2016; 143: 46-53.
11. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013; 497: 67-73.
12. Auguste A, Genestie C, De Bruyn M, et al. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. *Mod Pathol* 2018; 31: 1851-61.
13. Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase varepsilon (*POLE*) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. *Cancer* 2015; 121: 386-94.
14. Hoang LN, McConechy MK, Meng B, et al. Targeted mutation analysis of endometrial clear cell carcinoma. *Histopathology* 2015; 66: 664-74.
15. DeLair DF, Burke KA, Selenica P, et al. The genetic landscape of endometrial clear cell carcinomas. *J Pathol* 2017; 243: 230-41.
16. Billingsley CC, Cohn DE, Mutch DG, Hade EM, Goodfellow PJ. Prognostic significance of *POLE* exonuclease domain mutations in high-grade endometrioid endometrial cancer on survival and recurrence: a subanalysis. *Int J Gynecol Cancer* 2016; 26: 933-8.
17. Wortman BG, Creutzberg CL, Putter H, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. *Br J Cancer* 2018; 119: 1067-74.
18. Kommos FK, Karnezis AN, Kommos F, et al. *L1CAM* further stratifies endometrial carcinoma patients with no specific molecular risk profile. *Br J Cancer* 2018; 119: 480-6.

19. Espinosa I, Lee CH, D'Angelo E, Palacios J, Prat J. Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. *Am J Surg Pathol* 2017; 41: 1121-8.
20. Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: a TransPORTEC initiative. *Mod Pathol* 2015; 28: 836-44.
21. Bosse T, Nout RA, McAlpine JN, et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. *Am J Surg Pathol* 2018; 42: 561-8.
22. Le Gallo M, Rudd ML, Urlick ME, et al. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. *Cancer* 2017; 123: 3261-8.
23. Rosa-Rosa JM, Leskela S, Cristobal-Lana E, et al. Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. *Mod Pathol* 2016; 29: 1390-8.